Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Shire Plans Lanadelumab BLA Submission Following Positive Phase III HAE Results

Shire said it plans to submit a Biologics License Application (BLA) to the FDA for its long-acting plasma kallikrein-targeting ...

Forward this item to a colleague:

(Separate multiple addresses by commas)